<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01491919</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00029537</org_study_id>
    <secondary_id>HHSN275201000003I</secondary_id>
    <nct_id>NCT01491919</nct_id>
  </id_info>
  <brief_title>Safety Study of Lisinopril in Children and Adolescents With a Kidney Transplant</brief_title>
  <acronym>PTN_LISINO</acronym>
  <official_title>Safety and Pharmacokinetics of Lisinopril in Pediatric Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uptal Patel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The EMMES Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>OpAns, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The drug lisinopril is approved by the U.S. Food and Drug Administration for the treatment of
      high blood pressure, heart failure, and acute heart attacks in adult patients. In children
      over 6 years of age, lisinopril is approved for the treatment of high blood pressure.
      Lisinopril is in a group of medications called angiotensin-converting enzyme inhibitors
      (ACE). ACE inhibitors such as lisinopril work by decreasing certain chemicals that tighten
      the blood vessels so blood flows more smoothly and the heart can pump blood more efficiently.

      There is some information available about how children with high blood pressure absorb,
      distribute, metabolize, and eliminate lisinopril (this information about medication
      processing by the body is called pharmacokinetic data). However, there is no information
      about how children with high blood pressure who have received a kidney transplant process
      lisinopril. In addition to decreasing blood pressure, investigators believe that lisinopril
      may help kidney transplants work longer by reducing the activity of chemicals made by cells
      in kidney transplants that can lead to inflammation and injury. Such benefits have not been
      found with another group of blood pressure medications called calcium channel blockers, which
      are the most commonly used medication group to control high blood pressure in children after
      a kidney transplant. A clinical trial will be conducted in the future to compare which
      medication group helps kidney transplants in children last longer. To guide the selection of
      the best dose to test in future studies, investigators in this study will try to determine
      the safety profile, dose tolerability, and pharmacokinetics of lisinopril in children and
      adolescents (2-17 years of age) who have received a kidney transplant and have high blood
      pressure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) - Area Under the Plasma Concentration-time Curve (AUC)</measure>
    <time_frame>Day 14 (+/- 3 days) of lisinopril therapy at hours 0 (pre-dose) and 1,2,4,5,8,12 and 24 hrs after dose</time_frame>
    <description>At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of AUC. Geometric mean was calculated from all measurements.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK - Maximum Observed Concentration of Drug in Plasma (Cmax)</measure>
    <time_frame>Day14 (+/- 3 d) of dose at 0 hour and 1, 2, 4, 5, 8, 12, and 24 hrs after dose</time_frame>
    <description>At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of Cmax. Geometric mean was calculated from all measurements.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK - Time of the Maximum Observed Concentration in Plasma (Tmax)</measure>
    <time_frame>Day 14 (+/- 3 d) of dose at 0 hour and 1, 2, 4, 5, 8, 12, and 24 hrs after dose</time_frame>
    <description>At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of plasma lisinopril concentration. Medium was calculated from all measurements.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK - Oral Clearance (CL/F)</measure>
    <time_frame>Day 14 (+/- 3 d) of dose at 0 hour and at 1, 2, 4, 5, 8, 12, and 24 hrs after dose</time_frame>
    <description>At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of CL/F. Geometric mean was calculated from all measurements.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Renal Clearance (CLrenal)</measure>
    <time_frame>Day 14 (+/- 3 d) of dose at 0 hour and 1, 2, 4, 5, 8, 12, and 24 hrs after dose.</time_frame>
    <description>At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of CLrenal. Geometric mean was calculated from all measurements.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) During/After Study Drug Administration</measure>
    <time_frame>First dose of study drug to 30 days after final study visit for AEs and until resolution for SAEs</time_frame>
    <description>Number of Adverse Events (AEs) related and not related to study drug; number of Serious Adverse Events (SAEs) related and not related to study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Potassium Level From Baseline in Lisinopril-naive Participants</measure>
    <time_frame>At baseline visit and Day 14 prior to final study dose.</time_frame>
    <description>Potassium values will be obtained at Baseline and Day 14 prior to the final dose of study drug. Mean calculated from the two measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worse Post-dose Decrease in Estimated Glomerular Filtration Rate (eGFR) From Baseline in Lisinopril-naive Participants</measure>
    <time_frame>Baseline to Day 14 (+/- 3 days)</time_frame>
    <description>The eGFR at entry will need to be ≥ 30 ml/min/1.73m^2 to minimize concerns about an acute angiotensin-converting enzyme inhibitors (ACE-I)-mediated reduction in kidney function. eGFR ratio was computed from the worst post-dose value divided by the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Largest eGFR Percent Decrease From Baseline in Lisinopril-naive Participants</measure>
    <time_frame>Baseline to Day 14 (+/- 3 days)</time_frame>
    <description>The eGFR at entry will need to be ≥ 30 ml/min/1.73m^2 to minimize concerns about an acute angiotensin-converting enzyme inhibitor (ACEI) mediated reduction in kidney function.
Largest eGFR percent decrease from baseline reported in results section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urine Protein/Creatinine From Baseline in Lisinopril-naive Participants.</measure>
    <time_frame>Baseline to worst post-dose before Day 14 (+/- 3 days)</time_frame>
    <description>Change in urine protein/creatinine obtained as follows: Mean change (worst post-dose from baseline) presented for urine protein/creatinine ratio. Geometric mean of the ratio (worst post-dose / baseline with Geometric Coefficient of Variation percent (CV%) and greatest decrease presented for eGFR by dose group. Two patients in the high dose group had an evaluable urine protein/creatinine change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Blood Pressure From Baseline in Lisinopril-naive Participants</measure>
    <time_frame>Baseline to Day 14 (+/-3 days)</time_frame>
    <description>Ambulatory blood pressure readings were measured during the baseline/pre-study dose period using a SpaceLabs (Redmond, WA) device at home to avoid the confounding effects of venipuncture and abnormal sleep pattern.
Another blood pressure reading was performed at 1 day before the final dose of lisinopril (day before the last scheduled visit).
The mean of these measurements was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure From Baseline in Lisinopril-naive Participants</measure>
    <time_frame>Baseline to Day 14 (+/- 3 days)</time_frame>
    <description>Ambulatory blood pressure readings were measured during the baseline/pre-study dose period using a SpaceLabs (Redmond, WA) device at home to avoid the confounding effects of venipuncture and abnormal sleep pattern.
Another blood pressure reading was performed at 1 day before the final dose of lisinopril (day before the last scheduled visit).
The mean from these measurements was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure (BP) From Baseline in Lisinopril SOC Group</measure>
    <time_frame>Screening to Day 14 to 40</time_frame>
    <description>Lisinopril SOC participants were not given the ambulatory blood pressure machine to obtain readings at home, as was the Lisinopril-naive participants. Instead BP measurements were obtained during screening visit and compared to the Day 14 to 40 visit measurements. Note: these participants were not required to attend a Day 14 (+/-3 day visit) but did need to attend sometime between Day 14 to Day 40 (inclusive). The mean of these blood pressure measurements was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Blood Pressure From Baseline in Lisinopril SOC Group</measure>
    <time_frame>Screening to Day 14 to 40</time_frame>
    <description>Lisinopril SOC participants were not given the ambulatory blood pressure machine to obtain readings at home, as was the Lisinopril-naive participants. Instead BP measurements were obtained during screening visit and compared to the Day 14 to 40 visit measurements (note: the participants were not required to attend a Day 14 (+/-3 day visit) but did need to attend sometime between Day 14 to Day 40. The mean from the blood pressure measurements was calculated.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Low Dose: Lisinopril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Dose: Lisinopril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose: Lisinopril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril</intervention_name>
    <description>Subjects will be randomized to Low, Medium, or High dose of Lisinopril</description>
    <arm_group_label>Low Dose: Lisinopril</arm_group_label>
    <arm_group_label>Medium Dose: Lisinopril</arm_group_label>
    <arm_group_label>High Dose: Lisinopril</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Kidney transplant recipient

          2. Age 2-17 years, inclusive, at the time of first study dose

          3. Estimated GFR (eGFR) ≥30 ml/min/1.73m2, with stable allograft function as indicated by
             &lt;20% change in serum creatinine in the previous 30 days

          4. Stable immunosuppressive regimen, as indicated by &lt;10% change in dosage (in mg/kg) in
             these medications, within the 14 days prior to enrollment

          5. Systolic BP &gt;90th percentile for age, gender, and height, necessitating initiation or
             addition of an antihypertensive medication

          6. For females of child-bearing potential, a negative serum pregnancy test prior to
             initial dosing and agreement to practice appropriate contraceptive measures, including
             abstinence, from the time of the initial pregnancy testing through the remainder of
             the study (30 days after last administration of investigational agents).

        Exclusion Criteria:

          1. History of anaphylaxis attributable to lisinopril or other angiotensin-converting
             enzyme inhibitor (ACEI) agents (e.g.,enalapril, ramipril, quinapril)

          2. History of anaphylaxis attributable to iohexol or an iodine hypersensitivity

          3. Use of an angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor
             blocker, or renin antagonist within 30 days prior to enrollment

          4. Stage 2 hypertension defined as the &gt;99th percentile for age, height and gender + 5 mm
             Hg

          5. Blood Potassium value &gt; 6.0 milliequivalent / liter (mEq/L) (as determined at the
             screening visit)

          6. Previous participation in this study

          7. Physician concern that the participant may not adhere to the study protocol, based on
             prior behavior

          8. Current plasmapheresis treatment

          9. History of angioedema

         10. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Benjamin, MD, PhD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Howard Trachtman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>New York University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Uptal D Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adam Frymoyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University and Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospitals &amp; Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nichd.nih.gov/</url>
    <description>The Eunice Kennedy Shriver National Institute of Child Health and Human</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/druginfo/meds/a692051.html</url>
    <description>Information about Lisinopril</description>
  </link>
  <reference>
    <citation>National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004 Aug;114(2 Suppl 4th Report):555-76.</citation>
    <PMID>15286277</PMID>
  </reference>
  <reference>
    <citation>Knütter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M. Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19.</citation>
    <PMID>18713951</PMID>
  </reference>
  <reference>
    <citation>Lin JH, Chen IW, Ulm EH, Duggan DE. Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats. Drug Metab Dispos. 1988 May-Jun;16(3):392-6.</citation>
    <PMID>2900730</PMID>
  </reference>
  <reference>
    <citation>Hogg RJ, Delucchi A, Sakihara G, Wells TG, Tenney F, Batisky DL, Blumer JL, Vogt BA, Lo MW, Hand E, Panebianco D, Rippley R, Shaw W, Shahinfar S. A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. Pediatr Nephrol. 2007 May;22(5):695-701. Epub 2007 Jan 10.</citation>
    <PMID>17216247</PMID>
  </reference>
  <reference>
    <citation>Prinivil® (lisinopril tablets) package insert; Whitehouse Station, NJ: Merck &amp; Co., Inc.; 2003</citation>
  </reference>
  <reference>
    <citation>Mitsnefes MM, Khoury PR, McEnery PT. Early posttransplantation hypertension and poor long-term renal allograft survival in pediatric patients. J Pediatr. 2003 Jul;143(1):98-103.</citation>
    <PMID>12915832</PMID>
  </reference>
  <reference>
    <citation>Silverstein DM, Leblanc P, Hempe JM, Ramcharan T, Boudreaux JP. Tracking of blood pressure and its impact on graft function in pediatric renal transplant patients. Pediatr Transplant. 2007 Dec;11(8):860-7.</citation>
    <PMID>17976120</PMID>
  </reference>
  <reference>
    <citation>Mitsnefes MM, Omoloja A, McEnery PT. Short-term pediatric renal transplant survival: blood pressure and allograft function. Pediatr Transplant. 2001 Jun;5(3):160-5.</citation>
    <PMID>11422817</PMID>
  </reference>
  <reference>
    <citation>Cross NB, Webster AC, Masson P, O'connell PJ, Craig JC. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation. 2009 Jul 15;88(1):7-18. doi: 10.1097/TP.0b013e3181a9e960. Review.</citation>
    <PMID>19584673</PMID>
  </reference>
  <reference>
    <citation>Sorof JM, Goldstein SL, Brewer ED, Steiger HM, Portman RJ. Use of anti-hypertensive medications and post-transplant renal allograft function in children. Pediatr Transplant. 2000 Feb;4(1):21-7.</citation>
    <PMID>10731054</PMID>
  </reference>
  <reference>
    <citation>Hernández AA, Moreso F, Bayés B, Lauzurica R, Sánz-Guajardo D, Gómez-Huertas E, Pereira P, Paul J, Crespo J, Amenábar JJ, Oliver J, Serón D. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain. NDT Plus. 2010 Jun;3(Suppl_2):ii21-ii25.</citation>
    <PMID>20508862</PMID>
  </reference>
  <reference>
    <citation>Mitterbauer C, Heinze G, Kainz A, Kramar R, Hörl WH, Oberbauer R. ACE-inhibitor or AT2-antagonist therapy of renal transplant recipients is associated with an increase in serum potassium concentrations. Nephrol Dial Transplant. 2008 May;23(5):1742-6. doi: 10.1093/ndt/gfm864. Epub 2008 Jan 30.</citation>
    <PMID>18234845</PMID>
  </reference>
  <reference>
    <citation>Hiremath S, Fergusson D, Doucette S, Mulay AV, Knoll GA. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant. 2007 Oct;7(10):2350-60. Review.</citation>
    <PMID>17845569</PMID>
  </reference>
  <reference>
    <citation>Morath C, Schmied B, Mehrabi A, Weitz J, Schmidt J, Werner J, Buchler MW, Morcos M, Nawroth PP, Schwenger V, Doehler B, Opelz G, Zeier M. Angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers after renal transplantation. Clin Transplant. 2009 Dec;23 Suppl 21:33-6. doi: 10.1111/j.1399-0012.2009.01107.x. Review.</citation>
    <PMID>19930314</PMID>
  </reference>
  <reference>
    <citation>Iñigo P, Campistol JM, Lario S, Piera C, Campos B, Bescós M, Oppenheimer F, Rivera F. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol. 2001 Apr;12(4):822-7.</citation>
    <PMID>11274244</PMID>
  </reference>
  <reference>
    <citation>Nielsen SE, Schjoedt KJ, Astrup AS, Tarnow L, Lajer M, Hansen PR, Parving HH, Rossing P. Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. Diabet Med. 2010 Oct;27(10):1144-50. doi: 10.1111/j.1464-5491.2010.03083.x.</citation>
    <PMID>20854382</PMID>
  </reference>
  <reference>
    <citation>Halimi JM, Giraudeau B, Buchler M, Al-Najjar A, Etienne I, Laouad I, Bruyère F, Lebranchu Y. Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial. Clin Transplant. 2007 Mar-Apr;21(2):277-84.</citation>
    <PMID>17425758</PMID>
  </reference>
  <reference>
    <citation>Spooner N, Lad R, Barfield M. Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method. Anal Chem. 2009 Feb 15;81(4):1557-63. doi: 10.1021/ac8022839.</citation>
    <PMID>19154107</PMID>
  </reference>
  <reference>
    <citation>Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009 Mar;20(3):629-37. doi: 10.1681/ASN.2008030287. Epub 2009 Jan 21.</citation>
    <PMID>19158356</PMID>
  </reference>
  <reference>
    <citation>Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens. 2003 Oct;16(10):795-800.</citation>
    <PMID>14553956</PMID>
  </reference>
  <reference>
    <citation>Thompson KC, Zhao Z, Mazakas JM, Beasley CA, Reed RA, Moser CL. Characterization of an extemporaneous liquid formulation of lisinopril. Am J Health Syst Pharm. 2003 Jan 1;60(1):69-74.</citation>
    <PMID>12533979</PMID>
  </reference>
  <reference>
    <citation>CDER Approval Package for Prinivil®: Application Number 19-558/S-043. Clinical Pharmacology and Biopharmaceutics Review. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/19-558S043_Prinivil.cfm. Last accessed Jan. 6, 2011.</citation>
  </reference>
  <reference>
    <citation>Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M, Chatelut E, Grubb A, Veal GJ, Keir MJ, Holford NH. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol. 2009 Jan;24(1):67-76. doi: 10.1007/s00467-008-0997-5. Epub 2008 Oct 10.</citation>
    <PMID>18846389</PMID>
  </reference>
  <reference>
    <citation>Thomson AH, Kelly JG, Whiting B. Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension. Br J Clin Pharmacol. 1989 Jan;27(1):57-65.</citation>
    <PMID>2539850</PMID>
  </reference>
  <reference>
    <citation>Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11. 2002 May;(246):1-190.</citation>
    <PMID>12043359</PMID>
  </reference>
  <reference>
    <citation>Bazzoli C, Retout S, Mentré F. Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0. Comput Methods Programs Biomed. 2010 Apr;98(1):55-65. doi: 10.1016/j.cmpb.2009.09.012. Epub 2009 Nov 4.</citation>
    <PMID>19892427</PMID>
  </reference>
  <reference>
    <citation>Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witteman JC. ACE polymorphisms. Circ Res. 2006 May 12;98(9):1123-33. Review.</citation>
    <PMID>16690893</PMID>
  </reference>
  <reference>
    <citation>Wühl E, Witte K, Soergel M, Mehls O, Schaefer F; German Working Group on Pediatric Hypertension. Distribution of 24-h ambulatory blood pressure in children: normalized reference values and role of body dimensions. J Hypertens. 2002 Oct;20(10):1995-2007. Erratum in: J Hypertens. 2003 Nov;21(11):2205-6.</citation>
    <PMID>12359978</PMID>
  </reference>
  <reference>
    <citation>Soergel M, Kirschstein M, Busch C, Danne T, Gellermann J, Holl R, Krull F, Reichert H, Reusz GS, Rascher W. Oscillometric twenty-four-hour ambulatory blood pressure values in healthy children and adolescents: a multicenter trial including 1141 subjects. J Pediatr. 1997 Feb;130(2):178-84.</citation>
    <PMID>9042117</PMID>
  </reference>
  <reference>
    <citation>ESCAPE Trial Group, Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Möller K, Wigger M, Peruzzi L, Mehls O, Schaefer F. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009 Oct 22;361(17):1639-50. doi: 10.1056/NEJMoa0902066.</citation>
    <PMID>19846849</PMID>
  </reference>
  <reference>
    <citation>Knoll GA, Cantarovitch M, Cole E, Gill J, Gourishankar S, Holland D, Kiberd B, Muirhead N, Prasad R, Tibbles LA, Treleaven D, Fergusson D. The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation--study design. Nephrol Dial Transplant. 2008 Jan;23(1):354-8. Epub 2007 Sep 10.</citation>
    <PMID>17848393</PMID>
  </reference>
  <reference>
    <citation>Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, Hall K, Ray WA. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006 Jun 8;354(23):2443-51.</citation>
    <PMID>16760444</PMID>
  </reference>
  <reference>
    <citation>Urbina E, Alpert B, Flynn J, Hayman L, Harshfield GA, Jacobson M, Mahoney L, McCrindle B, Mietus-Snyder M, Steinberger J, Daniels S; American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee. Ambulatory blood pressure monitoring in children and adolescents: recommendations for standard assessment: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee of the council on cardiovascular disease in the young and the council for high blood pressure research. Hypertension. 2008 Sep;52(3):433-51. doi: 10.1161/HYPERTENSIONAHA.108.190329. Epub 2008 Aug 4.</citation>
    <PMID>18678786</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2011</study_first_submitted>
  <study_first_submitted_qc>December 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2011</study_first_posted>
  <results_first_submitted>April 27, 2015</results_first_submitted>
  <results_first_submitted_qc>June 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 8, 2015</results_first_posted>
  <last_update_submitted>June 15, 2015</last_update_submitted>
  <last_update_submitted_qc>June 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Uptal Patel</investigator_full_name>
    <investigator_title>Assoc Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>High Blood Pressure</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Renal Transplantation</keyword>
  <keyword>Kidney Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lisinopril</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low Dose: Lisinopril</title>
          <description>Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day</description>
        </group>
        <group group_id="P2">
          <title>Medium Dose: Lisinopril</title>
          <description>Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day</description>
        </group>
        <group group_id="P3">
          <title>High Dose: Lisinopril</title>
          <description>Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Insufficient PK sampling</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose: Lisinopril</title>
          <description>Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day</description>
        </group>
        <group group_id="B2">
          <title>Medium Dose: Lisinopril</title>
          <description>Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day</description>
        </group>
        <group group_id="B3">
          <title>High Dose: Lisinopril</title>
          <description>Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.9" spread="2.3"/>
                    <measurement group_id="B2" value="13.0" spread="3"/>
                    <measurement group_id="B3" value="9.5" spread="3.5"/>
                    <measurement group_id="B4" value="13.8" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated glomerular filtration rate (eGFR)</title>
          <description>Estimated glomerular filtration rate (eGFR) calculated by modified Schwartz formula [=0.413 x Length (cm)/serum creatinine (mg/dl)].
Note: text verified with protocol on 4/2/15 as '413xLength'. Added spaces for clarification.</description>
          <units>ml/min per 1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.5" spread="25.7"/>
                    <measurement group_id="B2" value="62" spread="16.7"/>
                    <measurement group_id="B3" value="89.3" spread="44.4"/>
                    <measurement group_id="B4" value="70.2" spread="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since transplant</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.8" spread="4.7"/>
                    <measurement group_id="B2" value="4.9" spread="3.4"/>
                    <measurement group_id="B3" value="0.9" spread="0.4"/>
                    <measurement group_id="B4" value="4.5" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-hispanic/non-latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.8" spread="19.4"/>
                    <measurement group_id="B2" value="50.2" spread="28.7"/>
                    <measurement group_id="B3" value="23.1" spread="3.0"/>
                    <measurement group_id="B4" value="51.3" spread="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (PK) - Area Under the Plasma Concentration-time Curve (AUC)</title>
        <description>At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of AUC. Geometric mean was calculated from all measurements.</description>
        <time_frame>Day 14 (+/- 3 days) of lisinopril therapy at hours 0 (pre-dose) and 1,2,4,5,8,12 and 24 hrs after dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day</description>
          </group>
          <group group_id="O3">
            <title>High Dose: Lisinopril</title>
            <description>Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK) - Area Under the Plasma Concentration-time Curve (AUC)</title>
          <description>At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of AUC. Geometric mean was calculated from all measurements.</description>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298" spread="46.5"/>
                    <measurement group_id="O2" value="640" spread="28.6"/>
                    <measurement group_id="O3" value="702" spread="66.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK - Maximum Observed Concentration of Drug in Plasma (Cmax)</title>
        <description>At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of Cmax. Geometric mean was calculated from all measurements.</description>
        <time_frame>Day14 (+/- 3 d) of dose at 0 hour and 1, 2, 4, 5, 8, 12, and 24 hrs after dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day</description>
          </group>
          <group group_id="O3">
            <title>High Dose: Lisinopril</title>
            <description>Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>PK - Maximum Observed Concentration of Drug in Plasma (Cmax)</title>
          <description>At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of Cmax. Geometric mean was calculated from all measurements.</description>
          <units>ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" spread="41.2"/>
                    <measurement group_id="O2" value="47.7" spread="25.1"/>
                    <measurement group_id="O3" value="58.0" spread="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Potassium Level From Baseline in Lisinopril-naive Participants</title>
        <description>Potassium values will be obtained at Baseline and Day 14 prior to the final dose of study drug. Mean calculated from the two measurements.</description>
        <time_frame>At baseline visit and Day 14 prior to final study dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day</description>
          </group>
          <group group_id="O3">
            <title>High Dose: Lisinopril</title>
            <description>Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Potassium Level From Baseline in Lisinopril-naive Participants</title>
          <description>Potassium values will be obtained at Baseline and Day 14 prior to the final dose of study drug. Mean calculated from the two measurements.</description>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.3"/>
                    <measurement group_id="O2" value="-0.3" spread="0.6"/>
                    <measurement group_id="O3" value="0.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Worse Post-dose Decrease in Estimated Glomerular Filtration Rate (eGFR) From Baseline in Lisinopril-naive Participants</title>
        <description>The eGFR at entry will need to be ≥ 30 ml/min/1.73m^2 to minimize concerns about an acute angiotensin-converting enzyme inhibitors (ACE-I)-mediated reduction in kidney function. eGFR ratio was computed from the worst post-dose value divided by the Baseline value.</description>
        <time_frame>Baseline to Day 14 (+/- 3 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day</description>
          </group>
          <group group_id="O3">
            <title>High Dose: Lisinopril</title>
            <description>Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Worse Post-dose Decrease in Estimated Glomerular Filtration Rate (eGFR) From Baseline in Lisinopril-naive Participants</title>
          <description>The eGFR at entry will need to be ≥ 30 ml/min/1.73m^2 to minimize concerns about an acute angiotensin-converting enzyme inhibitors (ACE-I)-mediated reduction in kidney function. eGFR ratio was computed from the worst post-dose value divided by the Baseline value.</description>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="14"/>
                    <measurement group_id="O2" value="1.02" spread="10"/>
                    <measurement group_id="O3" value="0.89" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK - Time of the Maximum Observed Concentration in Plasma (Tmax)</title>
        <description>At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of plasma lisinopril concentration. Medium was calculated from all measurements.</description>
        <time_frame>Day 14 (+/- 3 d) of dose at 0 hour and 1, 2, 4, 5, 8, 12, and 24 hrs after dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day</description>
          </group>
          <group group_id="O3">
            <title>High Dose: Lisinopril</title>
            <description>Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>PK - Time of the Maximum Observed Concentration in Plasma (Tmax)</title>
          <description>At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of plasma lisinopril concentration. Medium was calculated from all measurements.</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="4.0" upper_limit="8.1"/>
                    <measurement group_id="O2" value="5.0" lower_limit="4.0" upper_limit="8.0"/>
                    <measurement group_id="O3" value="4.5" lower_limit="4.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK - Oral Clearance (CL/F)</title>
        <description>At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of CL/F. Geometric mean was calculated from all measurements.</description>
        <time_frame>Day 14 (+/- 3 d) of dose at 0 hour and at 1, 2, 4, 5, 8, 12, and 24 hrs after dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day</description>
          </group>
          <group group_id="O3">
            <title>High Dose: Lisinopril</title>
            <description>Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>PK - Oral Clearance (CL/F)</title>
          <description>At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of CL/F. Geometric mean was calculated from all measurements.</description>
          <units>L/h/70 kg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" spread="61.2"/>
                    <measurement group_id="O2" value="18.6" spread="34.4"/>
                    <measurement group_id="O3" value="32.8" spread="54.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Renal Clearance (CLrenal)</title>
        <description>At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of CLrenal. Geometric mean was calculated from all measurements.</description>
        <time_frame>Day 14 (+/- 3 d) of dose at 0 hour and 1, 2, 4, 5, 8, 12, and 24 hrs after dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day</description>
          </group>
          <group group_id="O3">
            <title>High Dose: Lisinopril</title>
            <description>Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Renal Clearance (CLrenal)</title>
          <description>At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of CLrenal. Geometric mean was calculated from all measurements.</description>
          <units>L/h/70 kg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="60.4"/>
                    <measurement group_id="O2" value="3.4" spread="46.0"/>
                    <measurement group_id="O3" value="6.8" spread="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) During/After Study Drug Administration</title>
        <description>Number of Adverse Events (AEs) related and not related to study drug; number of Serious Adverse Events (SAEs) related and not related to study drug</description>
        <time_frame>First dose of study drug to 30 days after final study visit for AEs and until resolution for SAEs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lisinopril-naive</title>
            <description>These protocol participants were not randomized. Instead, the older age group (7-17 years) were first enrolled consecutively into each dose level, starting with the lowest dose level (0.1 mg/kg per day). After enrollment is complete in the low dose level for an eGFR strata, enrollment will commence for the intermediate (0.2 mg/kg per day) dosage in that strata, followed by the high (0.4 mg/kg per day) dosage level. Enrollment for the 2-6 years age group did not begin until enrollment in the older age group (7-17 years) for the low and intermediate dosage level at each eGFR strata is complete.</description>
          </group>
          <group group_id="O2">
            <title>Lisinopril Standard of Care (SOC)</title>
            <description>These protocol participants were enrolled and continued on the lisinopril dose prescribed as standard of care. They were assigned to the appropriate eGFR and dose level stratum (rounding to the closest dose level). Since the lisinopril dose was assigned based on standard of care, a patient was enrolled without regard to open/closed status of the dose stratum in this group. Therefore, over enrollment of a specific dose and eGFR stratum was allowed for participants enrolled he the Lisinopril-naive group to accommodate these valuable low-risk participants already taking lisinopril.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) During/After Study Drug Administration</title>
          <description>Number of Adverse Events (AEs) related and not related to study drug; number of Serious Adverse Events (SAEs) related and not related to study drug</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs not related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE not related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Largest eGFR Percent Decrease From Baseline in Lisinopril-naive Participants</title>
        <description>The eGFR at entry will need to be ≥ 30 ml/min/1.73m^2 to minimize concerns about an acute angiotensin-converting enzyme inhibitor (ACEI) mediated reduction in kidney function.
Largest eGFR percent decrease from baseline reported in results section.</description>
        <time_frame>Baseline to Day 14 (+/- 3 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day</description>
          </group>
          <group group_id="O3">
            <title>High Dose: Lisinopril</title>
            <description>Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Largest eGFR Percent Decrease From Baseline in Lisinopril-naive Participants</title>
          <description>The eGFR at entry will need to be ≥ 30 ml/min/1.73m^2 to minimize concerns about an acute angiotensin-converting enzyme inhibitor (ACEI) mediated reduction in kidney function.
Largest eGFR percent decrease from baseline reported in results section.</description>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Urine Protein/Creatinine From Baseline in Lisinopril-naive Participants.</title>
        <description>Change in urine protein/creatinine obtained as follows: Mean change (worst post-dose from baseline) presented for urine protein/creatinine ratio. Geometric mean of the ratio (worst post-dose / baseline with Geometric Coefficient of Variation percent (CV%) and greatest decrease presented for eGFR by dose group. Two patients in the high dose group had an evaluable urine protein/creatinine change.</description>
        <time_frame>Baseline to worst post-dose before Day 14 (+/- 3 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day</description>
          </group>
          <group group_id="O3">
            <title>High Dose: Lisinopril</title>
            <description>Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urine Protein/Creatinine From Baseline in Lisinopril-naive Participants.</title>
          <description>Change in urine protein/creatinine obtained as follows: Mean change (worst post-dose from baseline) presented for urine protein/creatinine ratio. Geometric mean of the ratio (worst post-dose / baseline with Geometric Coefficient of Variation percent (CV%) and greatest decrease presented for eGFR by dose group. Two patients in the high dose group had an evaluable urine protein/creatinine change.</description>
          <units>mg/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.6"/>
                    <measurement group_id="O2" value="-0.08" spread="0.15"/>
                    <measurement group_id="O3" value="-0.74" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diastolic Blood Pressure From Baseline in Lisinopril-naive Participants</title>
        <description>Ambulatory blood pressure readings were measured during the baseline/pre-study dose period using a SpaceLabs (Redmond, WA) device at home to avoid the confounding effects of venipuncture and abnormal sleep pattern.
Another blood pressure reading was performed at 1 day before the final dose of lisinopril (day before the last scheduled visit).
The mean of these measurements was calculated.</description>
        <time_frame>Baseline to Day 14 (+/-3 days)</time_frame>
        <population>Change in diastolic blood pressure from baseline is reported here for lisinopril-naive participants (not the standard of care group which are reported separately).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day</description>
          </group>
          <group group_id="O3">
            <title>High Dose: Lisinopril</title>
            <description>Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure From Baseline in Lisinopril-naive Participants</title>
          <description>Ambulatory blood pressure readings were measured during the baseline/pre-study dose period using a SpaceLabs (Redmond, WA) device at home to avoid the confounding effects of venipuncture and abnormal sleep pattern.
Another blood pressure reading was performed at 1 day before the final dose of lisinopril (day before the last scheduled visit).
The mean of these measurements was calculated.</description>
          <population>Change in diastolic blood pressure from baseline is reported here for lisinopril-naive participants (not the standard of care group which are reported separately).</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>eGFR 30-59 ml/min per 1.73m^2 (n=3, 1, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="20"/>
                    <measurement group_id="O2" value="7.0" spread="0"/>
                    <measurement group_id="O3" value="NA">no participants in this category</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>eGFR &gt;=60 ml/min per 1.73m^2 (n=3, 5, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="7.5"/>
                    <measurement group_id="O2" value="-6.0" spread="6.7"/>
                    <measurement group_id="O3" value="-4.0" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure From Baseline in Lisinopril-naive Participants</title>
        <description>Ambulatory blood pressure readings were measured during the baseline/pre-study dose period using a SpaceLabs (Redmond, WA) device at home to avoid the confounding effects of venipuncture and abnormal sleep pattern.
Another blood pressure reading was performed at 1 day before the final dose of lisinopril (day before the last scheduled visit).
The mean from these measurements was calculated.</description>
        <time_frame>Baseline to Day 14 (+/- 3 days)</time_frame>
        <population>Change in systolic blood pressure from baseline is reported here for lisinopril-naive participants (not the standard of care (SOC) group which are reported separately).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day</description>
          </group>
          <group group_id="O3">
            <title>High Dose: Lisinopril</title>
            <description>Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure From Baseline in Lisinopril-naive Participants</title>
          <description>Ambulatory blood pressure readings were measured during the baseline/pre-study dose period using a SpaceLabs (Redmond, WA) device at home to avoid the confounding effects of venipuncture and abnormal sleep pattern.
Another blood pressure reading was performed at 1 day before the final dose of lisinopril (day before the last scheduled visit).
The mean from these measurements was calculated.</description>
          <population>Change in systolic blood pressure from baseline is reported here for lisinopril-naive participants (not the standard of care (SOC) group which are reported separately).</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>eGFR 30-59 ml/min per 1.73m2 (n=3, 1, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="11.4"/>
                    <measurement group_id="O2" value="-6.0" spread="0"/>
                    <measurement group_id="O3" value="NA">no participants in this category</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>eGFR &gt;+60 ml/min per 1.732 (n=3, 5, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="4.0"/>
                    <measurement group_id="O2" value="-8.8" spread="11.7"/>
                    <measurement group_id="O3" value="-11.3" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure (BP) From Baseline in Lisinopril SOC Group</title>
        <description>Lisinopril SOC participants were not given the ambulatory blood pressure machine to obtain readings at home, as was the Lisinopril-naive participants. Instead BP measurements were obtained during screening visit and compared to the Day 14 to 40 visit measurements. Note: these participants were not required to attend a Day 14 (+/-3 day visit) but did need to attend sometime between Day 14 to Day 40 (inclusive). The mean of these blood pressure measurements was calculated.</description>
        <time_frame>Screening to Day 14 to 40</time_frame>
        <population>Change in systolic blood pressure from baseline is reported here for lisinopril SOCparticipants (not the Lisinopril-naive group which are reported separately).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day</description>
          </group>
          <group group_id="O3">
            <title>High Dose: Lisinopril</title>
            <description>Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure (BP) From Baseline in Lisinopril SOC Group</title>
          <description>Lisinopril SOC participants were not given the ambulatory blood pressure machine to obtain readings at home, as was the Lisinopril-naive participants. Instead BP measurements were obtained during screening visit and compared to the Day 14 to 40 visit measurements. Note: these participants were not required to attend a Day 14 (+/-3 day visit) but did need to attend sometime between Day 14 to Day 40 (inclusive). The mean of these blood pressure measurements was calculated.</description>
          <population>Change in systolic blood pressure from baseline is reported here for lisinopril SOCparticipants (not the Lisinopril-naive group which are reported separately).</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>eGFR 30-59 ml/min per 1.73m2 (n=2, 2, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="17"/>
                    <measurement group_id="O2" value="-1.0" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>eGFR &gt;=60 ml/min per 1.73m2 (n=5, 2, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="6.9"/>
                    <measurement group_id="O2" value="-1.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diastolic Blood Pressure From Baseline in Lisinopril SOC Group</title>
        <description>Lisinopril SOC participants were not given the ambulatory blood pressure machine to obtain readings at home, as was the Lisinopril-naive participants. Instead BP measurements were obtained during screening visit and compared to the Day 14 to 40 visit measurements (note: the participants were not required to attend a Day 14 (+/-3 day visit) but did need to attend sometime between Day 14 to Day 40. The mean from the blood pressure measurements was calculated.</description>
        <time_frame>Screening to Day 14 to 40</time_frame>
        <population>Change in diastolic blood pressure from baseline is reported here for lisinopril SOCparticipants (not the Lisinopril-naive group which are reported separately).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose: Lisinopril</title>
            <description>Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day</description>
          </group>
          <group group_id="O3">
            <title>High Dose: Lisinopril</title>
            <description>Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure From Baseline in Lisinopril SOC Group</title>
          <description>Lisinopril SOC participants were not given the ambulatory blood pressure machine to obtain readings at home, as was the Lisinopril-naive participants. Instead BP measurements were obtained during screening visit and compared to the Day 14 to 40 visit measurements (note: the participants were not required to attend a Day 14 (+/-3 day visit) but did need to attend sometime between Day 14 to Day 40. The mean from the blood pressure measurements was calculated.</description>
          <population>Change in diastolic blood pressure from baseline is reported here for lisinopril SOCparticipants (not the Lisinopril-naive group which are reported separately).</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>eGFR 30-59 ml/min per 1.73m2 (n=2, 2, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="5.7"/>
                    <measurement group_id="O2" value="-6.5" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>eGFR &gt;=60 ml/min per 1.73m2 (n=5, 2, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="14.0"/>
                    <measurement group_id="O2" value="-3.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Low Dose: Lisinopril</title>
          <description>Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day</description>
        </group>
        <group group_id="E2">
          <title>Medium Dose: Lisinopril</title>
          <description>Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day</description>
        </group>
        <group group_id="E3">
          <title>High Dose: Lisinopril</title>
          <description>Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Infusion site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Uptal Patel, MD</name_or_title>
      <organization>Duke Clinical Research Institute</organization>
      <phone>919-668-4601</phone>
      <email>uptal.patel@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

